Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Protective Effects of ω-3 PUFA in Anthracycline-Induced Cardiotoxicity: A Critical Review.

Serini S, Ottes Vasconcelos R, Nascimento Gomes R, Calviello G.

Int J Mol Sci. 2017 Dec 12;18(12). pii: E2689. doi: 10.3390/ijms18122689. Review.

2.

Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer.

Antonarakis ES, Tagawa ST, Galletti G, Worroll D, Ballman K, Vanhuyse M, Sonpavde G, North S, Albany C, Tsao CK, Stewart J, Zaher A, Szatrowski T, Zhou W, Gjyrezi A, Tasaki S, Portella L, Bai Y, Lannin TB, Suri S, Gruber CN, Pratt ED, Kirby BJ, Eisenberger MA, Nanus DM, Saad F, Giannakakou P; TAXYNERGY Investigators.

J Clin Oncol. 2017 Oct 1;35(28):3181-3188. doi: 10.1200/JCO.2017.72.4138. Epub 2017 Jun 20.

3.

Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.

Ho CM, Huang CJ, Huang SH, Chang SF, Cheng WF.

BMC Cancer. 2015 Oct 24;15:789. doi: 10.1186/s12885-015-1744-5.

4.

Role of Drug Metabolism in the Cytotoxicity and Clinical Efficacy of Anthracyclines.

Edwardson DW, Narendrula R, Chewchuk S, Mispel-Beyer K, Mapletoft JP, Parissenti AM.

Curr Drug Metab. 2015;16(6):412-26. Review.

5.

Gambogenic acid alters chemosensitivity of breast cancer cells to Adriamycin.

He Y, Ding J, Lin Y, Li J, Shi Y, Wang J, Zhu Y, Wang K, Hu X.

BMC Complement Altern Med. 2015 Jun 12;15:181. doi: 10.1186/s12906-015-0710-8.

6.

Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value.

Lehmann BD, Ding Y, Viox DJ, Jiang M, Zheng Y, Liao W, Chen X, Xiang W, Yi Y.

BMC Cancer. 2015 Mar 26;15:179. doi: 10.1186/s12885-015-1102-7.

7.

Preclinical profile of cabazitaxel.

Vrignaud P, Semiond D, Benning V, Beys E, Bouchard H, Gupta S.

Drug Des Devel Ther. 2014 Oct 13;8:1851-67. doi: 10.2147/DDDT.S64940. eCollection 2014. Review.

8.

Gene expression profiling reveals epithelial mesenchymal transition (EMT) genes can selectively differentiate eribulin sensitive breast cancer cells.

Dezső Z, Oestreicher J, Weaver A, Santiago S, Agoulnik S, Chow J, Oda Y, Funahashi Y.

PLoS One. 2014 Aug 29;9(8):e106131. doi: 10.1371/journal.pone.0106131. eCollection 2014.

9.

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.

Wang H, Vo T, Hajar A, Li S, Chen X, Parissenti AM, Brindley DN, Wang Z.

BMC Cancer. 2014 Jan 22;14:37. doi: 10.1186/1471-2407-14-37.

10.

SUMOylation inhibits FOXM1 activity and delays mitotic transition.

Myatt SS, Kongsema M, Man CW, Kelly DJ, Gomes AR, Khongkow P, Karunarathna U, Zona S, Langer JK, Dunsby CW, Coombes RC, French PM, Brosens JJ, Lam EW.

Oncogene. 2014 Aug 21;33(34):4316-29. doi: 10.1038/onc.2013.546. Epub 2013 Dec 23.

11.

New oral anticoagulants and the cancer patient.

Short NJ, Connors JM.

Oncologist. 2014 Jan;19(1):82-93. doi: 10.1634/theoncologist.2013-0239. Epub 2013 Dec 6. Review.

12.

Prognostic implication of HSPA (HSP70) in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy.

Nadin SB, Sottile ML, Montt-Guevara MM, Gauna GV, Daguerre P, Leuzzi M, Gago FE, Ibarra J, Cuello-Carrión FD, Ciocca DR, Vargas-Roig LM.

Cell Stress Chaperones. 2014 Jul;19(4):493-505. doi: 10.1007/s12192-013-0475-2. Epub 2013 Dec 5.

13.

Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

Fountzilas G, Kotoula V, Pectasides D, Kouvatseas G, Timotheadou E, Bobos M, Mavropoulou X, Papadimitriou C, Vrettou E, Raptou G, Koutras A, Razis E, Bafaloukos D, Samantas E, Pentheroudakis G, Skarlos DV.

PLoS One. 2013 Jul 23;8(7):e69256. doi: 10.1371/journal.pone.0069256. Print 2013.

14.

USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.

Giovinazzi S, Morozov VM, Summers MK, Reinhold WC, Ishov AM.

Cell Death Differ. 2013 May;20(5):721-31. doi: 10.1038/cdd.2012.169. Epub 2013 Jan 25.

15.

A marine anthraquinone SZ-685C overrides adriamycin-resistance in breast cancer cells through suppressing Akt signaling.

Zhu X, He Z, Wu J, Yuan J, Wen W, Hu Y, Jiang Y, Lin C, Zhang Q, Lin M, Zhang H, Yang W, Chen H, Zhong L, She Z, Chen S, Lin Y, Li M.

Mar Drugs. 2012 Apr;10(4):694-711. doi: 10.3390/md10040694. Epub 2012 Mar 23.

17.

Beyond taxanes: the next generation of microtubule-targeting agents.

Cortes J, Vidal M.

Breast Cancer Res Treat. 2012 Jun;133(3):821-30. doi: 10.1007/s10549-011-1875-6. Epub 2011 Nov 24. Review.

18.
19.

SZ-685C, a marine anthraquinone, is a potent inducer of apoptosis with anticancer activity by suppression of the Akt/FOXO pathway.

Xie G, Zhu X, Li Q, Gu M, He Z, Wu J, Li J, Lin Y, Li M, She Z, Yuan J.

Br J Pharmacol. 2010 Feb 1;159(3):689-97. doi: 10.1111/j.1476-5381.2009.00577.x. Epub 2010 Jan 28.

20.

Cell death induced by novel fluorinated taxanes in drug-sensitive and drug-resistant cancer cells.

Vobořilová J, Němcová-Fürstová V, Neubauerová J, Ojima I, Zanardi I, Gut I, Kovář J.

Invest New Drugs. 2011 Jun;29(3):411-23. doi: 10.1007/s10637-009-9368-8. Epub 2009 Dec 16.

Supplemental Content

Support Center